MA48793A - Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 - Google Patents
Procédés de fabrication et d'utilisation d'inhibiteurs de pde9Info
- Publication number
- MA48793A MA48793A MA048793A MA48793A MA48793A MA 48793 A MA48793 A MA 48793A MA 048793 A MA048793 A MA 048793A MA 48793 A MA48793 A MA 48793A MA 48793 A MA48793 A MA 48793A
- Authority
- MA
- Morocco
- Prior art keywords
- manufacturing
- methods
- pde9 inhibitors
- pde9
- inhibitors
- Prior art date
Links
- 229940076380 PDE9 inhibitor Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762511367P | 2017-05-26 | 2017-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA48793A true MA48793A (fr) | 2020-04-08 |
Family
ID=64396048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA048793A MA48793A (fr) | 2017-05-26 | 2018-05-25 | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11370795B2 (fr) |
EP (1) | EP3630772B1 (fr) |
JP (1) | JP2020527535A (fr) |
KR (1) | KR102627975B1 (fr) |
CN (2) | CN111183140B (fr) |
BR (1) | BR112019024877A2 (fr) |
CA (1) | CA3064004A1 (fr) |
DK (1) | DK3630772T3 (fr) |
EA (1) | EA201992721A1 (fr) |
FI (1) | FI3630772T3 (fr) |
HR (1) | HRP20240146T1 (fr) |
IL (1) | IL270792B2 (fr) |
LT (1) | LT3630772T (fr) |
MA (1) | MA48793A (fr) |
MX (2) | MX2019014049A (fr) |
PT (1) | PT3630772T (fr) |
RS (1) | RS65143B1 (fr) |
TW (2) | TWI791021B (fr) |
WO (1) | WO2018218104A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3865484B1 (fr) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Inhibiteur de pde9 présentant un squelette d'imidazo pyrazinone pour le traitement de maladies périphériques |
CN111183140B (zh) | 2017-05-26 | 2022-12-02 | 伊马拉公司 | 制备和使用pde9抑制剂的方法 |
CN109734653B (zh) * | 2019-02-21 | 2020-07-14 | 北京悦康科创医药科技股份有限公司 | 一种阿加曲班起始原料异构体杂质的拆分方法 |
WO2020202183A1 (fr) * | 2019-03-29 | 2020-10-08 | Mylan Laboratories Limited | Procédé de préparation d'upadacitinib et de ses intermédiaires |
CN114302724A (zh) * | 2019-04-05 | 2022-04-08 | 伊马拉公司 | 用于治疗镰状细胞病的pde9抑制剂 |
WO2022036111A1 (fr) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Méthodes et compositions pour le traitement de la maladie à hématies falciformes |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69519300T2 (de) | 1994-08-08 | 2001-05-31 | Debiopharm Sa | Stabiles arzneimittel enthaltend oxaliplatin |
EP1368022B1 (fr) | 2001-03-02 | 2007-06-20 | Debiopharm S.A. | Utilisation d'un flacon contenant une solution d'oxaliplatine |
JP2005508978A (ja) * | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療 |
US7326421B2 (en) | 2002-10-21 | 2008-02-05 | Kensey Nash Corporation | Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues |
GB0522569D0 (en) | 2005-11-04 | 2005-12-14 | Univ Bath | Biocompatible drug delivery device |
NZ580904A (en) | 2007-05-11 | 2012-02-24 | Pfizer | Amino-heterocyclic compounds for inhibiting pde9 |
TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
EP2619208B1 (fr) | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Composés imidazotriazinones |
MA37958B1 (fr) * | 2011-10-10 | 2018-10-31 | H Lundbeck As | Pde9i ayant un squelette imidazo pyrazinone |
EP3178820B1 (fr) * | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Inhibiteurs de pde9 avec squelette triazinone imidazo |
WO2013170069A1 (fr) | 2012-05-09 | 2013-11-14 | Massachusetts Institute Of Technology | Médicament, méthode, et dispositif d'administration de médicament pour le traitement du cancer de l'ovaire |
PL2890384T3 (pl) | 2012-08-31 | 2022-02-14 | Taris Biomedical Llc | Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę |
EP2983730B1 (fr) | 2013-04-10 | 2019-10-16 | Massachusetts Institute of Technology | Dispositifs et procédés d'administration de médicament locale pour traiter un cancer |
US10369340B2 (en) | 2013-08-12 | 2019-08-06 | Nanomedical Systems, Inc. | Device and method for sustained release of low water solubility therapeutic agent in solubilizer |
EP3865484B1 (fr) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Inhibiteur de pde9 présentant un squelette d'imidazo pyrazinone pour le traitement de maladies périphériques |
CN111183140B (zh) | 2017-05-26 | 2022-12-02 | 伊马拉公司 | 制备和使用pde9抑制剂的方法 |
-
2018
- 2018-05-25 CN CN201880049927.0A patent/CN111183140B/zh active Active
- 2018-05-25 WO PCT/US2018/034566 patent/WO2018218104A1/fr active Application Filing
- 2018-05-25 RS RS20240126A patent/RS65143B1/sr unknown
- 2018-05-25 EA EA201992721A patent/EA201992721A1/ru unknown
- 2018-05-25 DK DK18805780.6T patent/DK3630772T3/da active
- 2018-05-25 TW TW107117910A patent/TWI791021B/zh active
- 2018-05-25 EP EP18805780.6A patent/EP3630772B1/fr active Active
- 2018-05-25 HR HRP20240146TT patent/HRP20240146T1/hr unknown
- 2018-05-25 KR KR1020197038404A patent/KR102627975B1/ko active IP Right Grant
- 2018-05-25 PT PT188057806T patent/PT3630772T/pt unknown
- 2018-05-25 CA CA3064004A patent/CA3064004A1/fr active Pending
- 2018-05-25 BR BR112019024877A patent/BR112019024877A2/pt unknown
- 2018-05-25 JP JP2019565330A patent/JP2020527535A/ja active Pending
- 2018-05-25 CN CN202211419324.XA patent/CN115746003A/zh active Pending
- 2018-05-25 IL IL270792A patent/IL270792B2/en unknown
- 2018-05-25 TW TW112101128A patent/TW202334156A/zh unknown
- 2018-05-25 FI FIEP18805780.6T patent/FI3630772T3/fi active
- 2018-05-25 LT LTEPPCT/US2018/034566T patent/LT3630772T/lt unknown
- 2018-05-25 MA MA048793A patent/MA48793A/fr unknown
- 2018-05-25 MX MX2019014049A patent/MX2019014049A/es unknown
- 2018-05-25 US US16/615,347 patent/US11370795B2/en active Active
-
2019
- 2019-11-22 MX MX2023000191A patent/MX2023000191A/es unknown
-
2022
- 2022-04-19 US US17/723,669 patent/US20230183244A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PT3630772T (pt) | 2024-02-05 |
MX2023000191A (es) | 2023-02-09 |
US20200157108A1 (en) | 2020-05-21 |
RS65143B1 (sr) | 2024-02-29 |
TWI791021B (zh) | 2023-02-01 |
MX2019014049A (es) | 2020-07-28 |
CN111183140A (zh) | 2020-05-19 |
FI3630772T3 (fi) | 2024-01-31 |
CN115746003A (zh) | 2023-03-07 |
DK3630772T3 (da) | 2024-02-05 |
IL270792B2 (en) | 2024-01-01 |
EP3630772A4 (fr) | 2021-01-13 |
IL270792A (en) | 2020-01-30 |
LT3630772T (lt) | 2024-02-26 |
WO2018218104A1 (fr) | 2018-11-29 |
BR112019024877A2 (pt) | 2020-06-09 |
KR102627975B1 (ko) | 2024-01-19 |
EA201992721A1 (ru) | 2020-09-10 |
TW201908319A (zh) | 2019-03-01 |
CN111183140B (zh) | 2022-12-02 |
US20230183244A1 (en) | 2023-06-15 |
EP3630772B1 (fr) | 2023-11-01 |
HRP20240146T1 (hr) | 2024-04-12 |
US11370795B2 (en) | 2022-06-28 |
EP3630772A1 (fr) | 2020-04-08 |
TW202334156A (zh) | 2023-09-01 |
CA3064004A1 (fr) | 2018-11-29 |
JP2020527535A (ja) | 2020-09-10 |
IL270792B1 (en) | 2023-09-01 |
KR20200016891A (ko) | 2020-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
MA48793A (fr) | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
DK3710439T3 (da) | Kras g12c-hæmmere | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA45779A (fr) | Polypeptides immunomdulateurs et compositions et procédés associés | |
MA41613A (fr) | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA41558A (fr) | Compositions d'allergènes mélangés et leurs procédés d'utilisation | |
MA45094A (fr) | Matériaux souples antidérapants et procédés pour leur fabrication et leur utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA41296A (fr) | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci | |
ZA202002172B (en) | Pde9 inhibitor and use thereof |